Regeneron Pharmaceuticals (REGN) Key Ratios

$814.79

up-down-arrow $-18.77 (-2.25%)

As on 26-Aug-2026 16:25EDT

Market cap

info icon

$85,869 Mln

Revenue (TTM)

info icon

$15,535 Mln

P/E Ratio

info icon

20.5

P/B Ratio

info icon

2.7

Div. Yield

info icon

0.4 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 19.01 16.73 9.29 7.03 4.64
EBIT 82.30 1.08 6.31 2.53 -6.48
Net Profit 78.34 -6.81 -2.91 0.86 -6.95
EPS 79.84 -5.23 1.72 2.18 -6.23
Book Value -- -- 12.72 13.51 24.23
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 33.8940.0933.6136.7734.05
Net Margin info --42.0227.86----
Return on equity info 15.6924.4413.7514.8715.95
Return on Capital info 14.2721.21--13.6514.53
Return on Assets info 12.2218.099.7111.5012.46
Debt to Equity (x) info ----0.060.090.09
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
13.65
14.53
14.63
18.53
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

13.75

Higher than Peers by 54.04

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
13.75
14.87
15.95
16.26
20.94
Peer Median
-40.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

9.71

Higher than Peers by 40.55

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
9.71
11.50
12.46
12.69
15.88
Peer Median
-30.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

33.61

Higher than Peers by 115.82

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
33.61
36.77
34.05
30.85
40.40
Peer Median
-82.21
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

27.86

Higher than Peers by 117.75

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
27.86
31.41
31.07
30.14
35.12
Peer Median
-89.88
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

9.29

Lower than Peers by 44.74

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
9.29
0.01
0.08
0.08
-0.24
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

6.31

Higher than Peers by 7.27

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
6.31
9.09
19.47
-17.71
-47.58
Peer Median
-0.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-2.91

Higher than Peers by 4.27

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
-2.91
2.09
11.61
-8.87
-46.28
Peer Median
-7.19
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

1.72

Lower than Peers by 12.71

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
1.72
0.08
0.12
-0.09
-0.47
Peer Median
14.43
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

7.70

Higher than Peers by 18.16

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
7.70
--
--
--
--
Peer Median
-10.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.06

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
0.06
0.09
0.09
0.10
0.12
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
0.00
--
--
0.03
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

3.34

Lower than Peers by 2.47

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
3.34
4.13
4.73
5.69
5.06
Peer Median
5.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.78

Lower than Peers by 2.92

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
2.78
3.39
3.95
4.94
4.29
Peer Median
5.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

94.25

Higher than Peers by 96.34

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
94.25
120.42
87.59
55.44
82.80
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

42.26

Higher than Peers by 23.29

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
42.26
40.03
43.74
43.21
43.78
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.35

Higher than Peers by 0.28

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
0.35
0.37
0.40
0.42
0.45
Peer Median
0.07
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
152.19
152.76
153.09
170.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
546.66
525.29
1,029.66
466.22
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
150.27
129.39
247.12
123.51
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
--
548.59
548.65
935.63
513.22
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

20.45

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
20.45
18.42
18.37
25.31
18.96
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.68

Lower than Peers by 2.67

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
2.68
2.65
2.76
3.85
3.63
Peer Median
5.35
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.44

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
0.44
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

13.88

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
13.88
13.25
14.06
22.71
14.68
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

85,869

Higher than Peers by 85,721

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Regeneron Pharmaceuticals (REGN)
85,869
--
--
--
--
Peer Median
147
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...